Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 228.5% in December

Windtree Therapeutics, Inc. (NASDAQ:WINT) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 497,000 shares, a growth of 228.5% from the November 30th total of 151,300 shares. Based on an average trading volume of 1,660,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 5.6% of the company’s shares are sold short.

Windtree Therapeutics Stock Down 1.6 %

NASDAQ WINT opened at $0.31 on Friday. Windtree Therapeutics has a 52 week low of $0.29 and a 52 week high of $14.75. The firm has a market capitalization of $2.79 million, a price-to-earnings ratio of -0.02 and a beta of 0.54. The company has a fifty day moving average of $0.54 and a two-hundred day moving average of $3.36.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $7.00 price objective on shares of Windtree Therapeutics in a research note on Wednesday, December 4th.

About Windtree Therapeutics

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.